Unlocking more answers
in immunodiagnostics

EVALUTION® leverages high quality analytical performance from conventional immunodiagnostic approaches with the unique capability to quantify and monitor binding reactions in real-time. This provides the user with novel, timely and hence highly actionable information.

In the spotlight

"Making more donor organs available for successful transplantation is essential in order to shorten waiting times and reduce mortality rates on the transplant waiting list. Because of their unique capability of running very fast immunoassays, we approached MyCartis to work on an assay for the real-time and timely assessment of donor organs undergoing ex-vivo perfusion."

Prof.Dr. Andrew Fisher ,
Academic Director and Honorary Consultant Physician, Institute of Transplantation, Freeman Hospital,
Newcastle Upon Tyne Hospitals NHS Foundation Trust.

Making the difference

Evalution® brings significant added value in following domains

Emergency diagnostics

Evalution® runs fast immunoassay panels consisting of biomarkers of highly variable concentration

Patient & therapy monitoring

Evalution® can measure highly variable biomarker panels real-time

More effective immune monitoring

Evalution® is the first solution able to qualify [how strong, how fast] an immune response directly from a clinical sample, on top of the current practice of quantification [how much] and specification [how specific].”

Get inspired on how our technology can be relevant for you

Evalution® platform configurations

to take you from research to commercial applications

See how you can partner with MyCartis

MyCartis offers an open platform approach allowing partners to co-develop assays or port existing assay products on the platform. MyCartis also supports an OEM approach (DMAT® technology inside) in which case MyCartis’ technology is integrated in partner’s existing or new instruments.

Meet our knowledge bank

Join us to unlock more answers